These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3390532)

  • 41. Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes.
    Hathirat P; Areekul S; Isarangkura P; Chantachum Y
    J Med Assoc Thai; 1989 Jan; 72 Suppl 1():121-4. PubMed ID: 2732632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beta-thalassaemia--the Johannesburg experience.
    Poole JE; Cohn RJ; Roode H; Spector I
    S Afr Med J; 1989 Apr; 75(8):367-70. PubMed ID: 2652340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia.
    Hyman CB; Agness CL; Rodriguez-Funes R; Zednikova M
    Ann N Y Acad Sci; 1985; 445():293-303. PubMed ID: 3860133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H; Goshen J; Carmi D; Yaniv I; Kaplinsky C; Cohen IJ; Zaizov R
    Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Experience with desferrioxamine treatment by intravenous administration, in thalassemia].
    Barcellona R; Masseria R; Palmigiano C; Amato GM
    Minerva Pediatr; 1979 May; 31(10):809-12. PubMed ID: 470859
    [No Abstract]   [Full Text] [Related]  

  • 46. [Longitudinal growth of patients with homozygote beta-thalassemia during continuous subcutaneous infusion of deferoxamine].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 Jan; 111(5):176-81. PubMed ID: 3943469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L; Atti G; De Sanctis V; Candini G
    Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S; Cossu P; Sanna G; Frau F; Loi E; Lobrano R; Nucaro A; Toccafondi C; Cornacchia G; Loi A; Cao A
    Acta Haematol; 1982; 67(1):49-56. PubMed ID: 6800202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation of iron overload in thalassemia].
    Piga A; Davico S; Magliano M; Luzzatto L; Sandri A; Gabutti V
    Pediatr Med Chir; 1986; 8(1):9-13. PubMed ID: 3725619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term desferrioxamine therapy in thalassemia.
    Modell CB; Beck J
    Ann N Y Acad Sci; 1974; 232(0):201-10. PubMed ID: 4528634
    [No Abstract]   [Full Text] [Related]  

  • 52. The management of iron chelation therapy.
    Pippard MJ; Callender ST
    Br J Haematol; 1983 Aug; 54(4):503-7. PubMed ID: 6871105
    [No Abstract]   [Full Text] [Related]  

  • 53. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
    Lévy G; Bachelot C; Joannard A; Bost M
    Arch Fr Pediatr; 1980 May; 37(5):299-303. PubMed ID: 7469704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maintenance treatment with desferrioxamine via subcutaneous injections in a patient with HbE thalassaemia.
    van Deursen CT; Goey SH; Fickers MM
    Neth J Med; 1988 Oct; 33(3-4):178-81. PubMed ID: 3226450
    [No Abstract]   [Full Text] [Related]  

  • 55. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
    Aldouri MA; Wonke B; Hoffbrand AV; Flynn DM; Laulicht M; Fenton LA; Scheuer PJ; Kibbler CC; Allwood CA; Brown D
    J Clin Pathol; 1987 Nov; 40(11):1353-9. PubMed ID: 3121679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.
    Weiner M; Karpatkin M; Hart D; Seaman C; Vora SK; Henry WL; Piomelli S
    J Pediatr; 1978 Apr; 92(4):653-8. PubMed ID: 633033
    [No Abstract]   [Full Text] [Related]  

  • 57. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 59. Thalassemia.
    Brown EB
    Prog Clin Biol Res; 1983; 127():33-42. PubMed ID: 6889403
    [No Abstract]   [Full Text] [Related]  

  • 60. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.